KR970705400A - 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) - Google Patents

골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)

Info

Publication number
KR970705400A
KR970705400A KR1019970701532A KR19970701532A KR970705400A KR 970705400 A KR970705400 A KR 970705400A KR 1019970701532 A KR1019970701532 A KR 1019970701532A KR 19970701532 A KR19970701532 A KR 19970701532A KR 970705400 A KR970705400 A KR 970705400A
Authority
KR
South Korea
Prior art keywords
bisphosphonic acid
hormone
bone active
bone
hydroxyethane
Prior art date
Application number
KR1019970701532A
Other languages
English (en)
Inventor
죤 알토르프 베반
안 던바르 게데스
Original Assignee
레이셔 야코버스 코넬리스
더 프록터 앤드 갬블 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레이셔 야코버스 코넬리스, 더 프록터 앤드 갬블 캄파니 filed Critical 레이셔 야코버스 코넬리스
Publication of KR970705400A publication Critical patent/KR970705400A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 하기의 단계를 포함하는 골 대사성 질환을 갖는 인간 또는 기타 동물 피검자의 치료방법을 제공한다; (a) 약 6개월 이상의 기간 동안, 골 활성 포스포네이트의 안전 유효량을 피검자에게 투여하는 단계; (b) 약 3 내지 약 12개월의 기간 동안, 부갑상선 호르몬의 안전 유효량을 피검자에게 투여하는 단계.

Description

골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법.(METHODS FOR THE TREATMENT OF OSTEOPOROSIS USING BONE ACTIVE PHOSPHONATES AND PARATHYROID HORMONE)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기의 단계를 포함하는 골 대사성 질환을 갖는 인간 또는 기타 동물 피검자의 치료방법;(a)약 6개월 이상의 기간 동안, 골 활성 포스포네이트의 안전 유효량을 피검자에게 투여하는 단계; (b)약 3 내지 약 12개월의 기간 동안, 부갑상선 호르몬의 안전 유효량을 피검자에게 투여하는 단계.
  2. 제1항에 있어서, 단계 (b)에서, 상기 부갑상선 호르몬을 약 6개월 동안 투여하는 인간 또는 기타 동물 피검자의 치료 방법.
  3. 제1항에 있어서, 상기 단계 (a)와 (b)를 1 내지 6회 반복하는 인간 또는 기타 동물 피검자의 치료 방법.
  4. 제3항에 있어서, 단계 (b) 동안 골 활성 포스포네이트를 더 투여하는 것을 포함하는 인가 또는 기타 동물 피검자의 치료 방법.
  5. 제2항에 있어서, 상기 포스포네이트 화합물이 옥시에탄-1,1-비스포스폰산; 디클로로메탄 비스포스폰산; 3-아미노-1-히드록시프로판-1,1-비스포스폰산; 6-아미노-1-히드록시헥산-1,1-비스포스폰산;4-아미노-1-히드록시부턴-1,1-비스포스폰산; 2-(3-피리딜)-1-히드록시에탄-1,1-비스포스폰산;2-(N-이미다졸릴)-1-히드록시에탄-1,1-비스포스폰산; 3-(N-펜틸-N-메틸아미노)-1-히드록시프로판-1,1-비스포스폰산; 3-(N-피롤리디노)-1-히드록시프로판-1,1-비스포스폰산; N-시클로로헵틸아미노메탄비스포스폰산; S-(p-클로로페닐)티오메탄비스포스폰산; 7-(디히드로-1-피린딘)메탄 비스포스폰산; (7-디히드로-1-피린딘)히드록시메탄 비스포스폰산; (6-디히드로-2-피린딘)히드록시메탄비스포스폰산; 2-(6-피롤로피리딘)-1-히드록시에탄-1,1-비스포스폰산; 및 약제학적으로 허용 가능한 그의 염 및 그의 에스테르로 구성된 군으로부터 선택된 비스포스포네이트인, 인간 또는 기타 동물 피검자의 치료 방법.
  6. 제5항에 있어서, 상기 비스포스포네이트가 2-(3-피리딜)-1-히드록시에탄-1,1-비스포스폰산인 인간 또는 기타 동물 피검자의 치료 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701532A 1994-09-09 1995-09-06 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) KR970705400A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30392594A 1994-09-09 1994-09-09
US08/303,925 1994-09-09
PCT/US1995/011335 WO1996007417A1 (en) 1994-09-09 1995-09-06 Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone

Publications (1)

Publication Number Publication Date
KR970705400A true KR970705400A (ko) 1997-10-09

Family

ID=23174289

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701532A KR970705400A (ko) 1994-09-09 1995-09-06 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)

Country Status (8)

Country Link
EP (1) EP0779812A4 (ko)
JP (1) JPH10505090A (ko)
KR (1) KR970705400A (ko)
CN (1) CN1157565A (ko)
AU (1) AU686458B2 (ko)
CA (1) CA2199252A1 (ko)
IL (1) IL115224A0 (ko)
WO (1) WO1996007417A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
NO2459176T3 (ko) 2009-07-31 2018-02-24
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4868164A (en) * 1986-12-19 1989-09-19 Norwich Eaton Pharmaceuticals, Inc. Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
US5403824A (en) * 1993-03-19 1995-04-04 The Procter & Gamble Company Methods for the treatment of osteoporosis

Also Published As

Publication number Publication date
EP0779812A1 (en) 1997-06-25
AU3547595A (en) 1996-03-27
EP0779812A4 (en) 1997-09-10
AU686458B2 (en) 1998-02-05
WO1996007417A1 (en) 1996-03-14
IL115224A0 (en) 1995-12-31
JPH10505090A (ja) 1998-05-19
CN1157565A (zh) 1997-08-20
CA2199252A1 (en) 1996-03-14

Similar Documents

Publication Publication Date Title
US5366965A (en) Regimen for treatment or prophylaxis of osteoporosis
ATE150646T1 (de) Behandlung von peridontalkrankheiten mit alendronat
AU693541B2 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
JPH08505142A (ja) 骨損失を治療及び予防するためのビスホスホネート/エストロゲン療法
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
ATE289199T1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
ATE210643T1 (de) Prostaglandin-analoga zur behandlung von osteoporose
HUP0204114A2 (hu) Bifoszfonáttartalmú parenterális gyógyászati készítmény
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
EP0573604B1 (en) Methods for the treatment of osteoporosis
JPH07502507A (ja) ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
FI110667B (fi) Menetelmä farmaseuttisen valmisteen valmistamiseksi
KR970705400A (ko) 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
DE01201913T1 (de) Methoden zur Hemmung der Knochenresorption
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
KR970705399A (ko) 골다공증용 포스포네이트 및 부갑상성 호르몬(phosphonates and parathyroid hormone for osteoporosis)
RU2004122433A (ru) Способ лечения костных нарушений
JP2000504718A (ja) 骨吸収を予防するための局所用ビスホスホネート
CA2183764C (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
CO4410200A1 (es) Metodos para el tratamiento de osteoporosis usando fosfona- tos activos de huesos y hormonas paratiroidales
MXPA96005327A (en) Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee